VALLEY FORGE, Pa.--(BUSINESS WIRE)--Jun. 4, 2009--
AmerisourceBergen Corporation (NYSE:ABC) today announced that J.
Lawrence Wilson, 73, a member of the Company’s Board of Directors has
chosen to retire from the Board effective immediately.
Richard C. Gozon, AmerisourceBergen Chairman of the Board of Directors,
said, “Larry’s insight, judgment and commitment to shareholder interests
have made a significant contribution to the success of the Company and
the effectiveness of the Board of Directors. We will miss him, and wish
him well in his retirement.”
Mr. Wilson had been a member of the Board since AmerisourceBergen’s
inception almost eight years ago and previously served on the
AmeriSource Health Board of Directors, a predecessor company.
With Mr. Wilson’s retirement, the AmerisourceBergen Board currently has
eight members. The AmerisourceBergen Board of Directors will conduct a
search to fill the vacancy returning it to nine members.
About AmerisourceBergen
AmerisourceBergen is one of the world's largest pharmaceutical services
companies serving the United States, Canada and selected global markets.
Servicing both pharmaceutical manufacturers and healthcare providers in
the pharmaceutical supply channel, the Company provides drug
distribution and related services designed to reduce costs and improve
patient outcomes. AmerisourceBergen's service solutions range from
pharmacy automation and pharmaceutical packaging to reimbursement and
pharmaceutical consulting services. With more than $70 billion in annual
revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and
employs approximately 10,000 people. AmerisourceBergen is ranked #26 on
the Fortune 500 list. For more information, go to www.amerisourcebergen.com.
FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements about
AmerisourceBergen’s future business and financial performance, estimates
and prospects. These statements are based on management’s current
expectations and are subject to uncertainty and changes in
circumstances. Actual results may vary materially from the expectations
contained in the forward-looking statements. The following factors,
among others, could cause actual results to differ materially from those
described in any forward-looking statements: changes in pharmaceutical
market growth rates; the loss of one or more key customer or supplier
relationships; changes in customer mix; customer delinquencies, defaults
or insolvencies; supplier defaults or insolvencies; changes in
pharmaceutical manufacturers’ pricing and distribution policies or
practices; adverse resolution of any contract or other dispute with
customers or suppliers; federal and state government enforcement
initiatives to detect and prevent suspicious orders of controlled
substances and the diversion of controlled substances; changes in U.S.
legislation or regulatory action affecting pharmaceutical product
pricing or reimbursement policies, including under Medicaid and
Medicare; changes in regulatory or clinical medical guidelines and/or
labeling for the pharmaceuticals we distribute, including certain anemia
products; price inflation in branded pharmaceuticals and price deflation
in generics; significant breakdown or interruption of our information
technology systems; our inability to implement an enterprise resource
planning (ERP) system to handle business and financial processes within
AmerisourceBergen Drug Corporation’s operations and our corporate
functions without operating problems and/or cost overruns; success of
integration, restructuring or systems initiatives; interest rate and
foreign currency exchange rate fluctuations; economic, business,
competitive and/or regulatory developments in Canada, the United Kingdom
and elsewhere outside of the United States; the impact of divestitures
or the acquisition of businesses that do not perform as we expect or
that are difficult for us to integrate or control; our inability to
successfully complete any other transaction that we may wish to pursue
from time to time; changes in tax legislation or adverse resolution of
challenges to our tax positions; increased costs of maintaining, or
reductions in our ability to maintain adequate liquidity and financing
sources; continued volatility and further deterioration of the capital
and credit markets; and other economic, business, competitive, legal,
tax, regulatory and/or operational factors affecting our business
generally. Our most recent annual report on Form 10-K, quarterly
reports on Forms 10-Q and current reports 8-K (which we may revise or
supplement in future reports filed to the SEC) provide additional
information about these risks, uncertainties and other matters. We do
not undertake to update our forward-looking statements.
Source: AmerisourceBergen Corporation
AmerisourceBergen Corporation
Michael N. Kilpatric
610-727-7118
mkilpatric@amerisourcebergen.com